The statements below are read from Chandra Bhagat Pharma Limited’s filed results, 3 filed quarters and 12 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: H2 FY25-26 · filed May 26, 2026 · audited
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | H2 FY25Mar 2025 | H1 FY26Sep 2025 | H2 FY26Mar 2026Latest | YoYlatest |
|---|---|---|---|---|
| Sales | 21.8 | 25.5 | 90.7 | n/m |
| 22.1 | 24.2 | 88.5 | n/m | |
| Operating profit | -0.26 | 1.37 | 2.19 | n/m |
| OPM % | -1.2% | 5.4% | 2.4% | +3.6 pp |
| Other income | 2.45 | 0.34 | 3.01 | +23.0% |
| Interest | 1.10 | 0.81 | 1.19 | +8.5% |
| Depreciation | 0.54 | 0.61 | 0.49 | -9.5% |
| Profit before tax | 0.55 | 0.29 | 3.52 | n/m |
| Tax % | 68.7% | 21.6% | 26.2% | -42.6 pp |
| Net profit | 0.17 | 0.23 | 2.60 | n/m |
| EPS (₹) | 0.23 | 0.30 | 3.44 | n/m |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
